MPO and irritable bowel syndrome: Studies have shown that butyrate may inhibit myeloperoxidase (MPO) activity attenuating the grade of inflammation in colonic mucosa, and regulates reactive oxygen species (ROS) generation in healthy patients and those with inflammatory bowel diseases (IBD)7,.8